United States - English - NLM (National Library of Medicine)

patriot pharmaceuticals, llc - oxybutynin chloride (unii: l9f3d9renq) (oxybutynin - unii:k9p6mc7092) - oxybutynin chloride 5 mg - oxybutynin chloride is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. oxybutynin chloride extended release tablets are also indicated for the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida). oxybutynin chloride extended release tablets are contraindicated in patients with urinary retention, gastric retention and other severe decreased gastrointestinal motility conditions, uncontrolled narrow-angle glaucoma. oxybutynin chloride extended release tablets are also contraindicated in patients who have demonstrated hypersensitivity to the drug substance or other components of the product. there have been reports of hypersensitivity reactions, including anaphylaxis and angioedema. pregnancy category b. there are no adequate and well-controlled studies using oxybutynin chloride extended release tablets in pregnant wom

Australia - English - Department of Health (Therapeutic Goods Administration)

actavis pty ltd - oxybutynin -

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - oxybutynin 36mg - transdermal patch - 3.9 mg/24h - active: oxybutynin 36mg excipient: duro-tak 87-2888 acrylic adhesive backing film. scotchpak 9739 release liner (grade 10393 s 3 cl pet 4400b/000) triacetin - the treatment of overactive bladder with symptoms of urinary frequency, urgency or incontinence or any combination of these symptoms.

Canada - English - Health Canada

patriot a division of janssen inc - oxybutynin chloride - tablet (extended-release) - 5mg - oxybutynin chloride 5mg - antimuscarinics

Canada - English - Health Canada

patriot a division of janssen inc - oxybutynin chloride - tablet (extended-release) - 10mg - oxybutynin chloride 10mg - antimuscarinics

Canada - English - Health Canada

patriot a division of janssen inc - oxybutynin chloride - tablet (extended-release) - 15mg - oxybutynin chloride 15mg - antimuscarinics

Australia - English - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - oxybutynin, quantity: 36 mg - drug delivery system, transdermal - excipient ingredients: triacetin; ethyl acetate; povidone; 2-ethylhexyl acrylate; hexamethylene glycol dimethacrylate; cyclohexane; dilauroyl peroxide; isopropyl alcohol; dimeticonol; methicone; dibutyltin diacetate; heptane; toluene; aminoethylaminopropyl trimethoxysilane; polyethylene terephthalate; ethylene/vinyl acetate copolymer - oxytrol is indicated for the treatment of overactive bladder with symptoms of urinary frequency, urgency or incontinence or any combination of these symptoms.

United States - English - NLM (National Library of Medicine)

advagen pharma limited - oxybutynin chloride (unii: l9f3d9renq) (oxybutynin - unii:k9p6mc7092) - oxybutynin chloride is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. oxybutynin chloride extended-release tablets are also indicated for the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida). oxybutynin chloride extended-release tablets are contraindicated in patients with urinary retention, gastric retention and other severe decreased gastrointestinal motility conditions, uncontrolled narrow-angle glaucoma. oxybutynin chloride extended-release tablets are also contraindicated in patients who have demonstrated hypersensitivity to the drug substance or other components of the product. there have been reports of hypersensitivity reactions, including anaphylaxis and angioedema. risk summary there are no adequate data on oxybutynin chloride extended-release tablets use in pregnant women to evaluate for a drug-asso